FDA OKs Pluristem production facility, shares jump

    The FDA has approved Pluristem Therapeutics' (PSTI +5.9%) request to produce PLacental eXpanded (PLX) cell products at a new manufacturing facility.

    The FDA's authorization adds to that of the Paul-Ehrlich-Institute (PEI) in Germany.

    The plant can produce approximately 150,000 doses of PLX cells a year. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs